BeyondSpring annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeyondSpring reported $0 in revenue for fiscal 2025.
View full BeyondSpring company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$1.4M | −100.00% |
| 2022 | 2022-12-31 | $1.4M | $0 | 0.00% |
| 2021 | 2021-12-31 | $1.4M | $1.2M | +650.56% |
| 2020 | 2020-12-31 | $180,000 | $180,000 | — |
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | $0 | — |
| 2017 | 2017-12-31 | $0 | $0 | — |
| 2016 | 2016-12-31 | $0 | $0 | — |
| 2015 | 2015-12-31 | $0 | $0 | — |
| 2014 | 2014-12-31 | $0 | — | — |
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q1 2025 | 2025-03-31 | $0 | $0 | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | — | — |
| Q2 2024 | 2024-06-30 | $0 | — | — |
| Q1 2024 | 2024-03-31 | $0 | — | — |
| Q4 2021 | 2021-12-31 | $338,000 | — | — |
| Q3 2021 | 2021-09-30 | $337,000 | $337,000 | — |
| Q2 2021 | 2021-06-30 | $338,000 | $338,000 | — |
| Q1 2021 | 2021-03-31 | $338,000 | — | — |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q2 2020 | 2020-06-30 | $0 | $0 | — |
| Q4 2019 | 2019-12-31 | $0 | — | — |
| Q3 2019 | 2019-09-30 | $0 | — | — |
| Q2 2019 | 2019-06-30 | $0 | $0 | — |
| Q1 2019 | 2019-03-31 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $0 | — | — |
| Q1 2017 | 2017-03-31 | $0 | — | — |
BeyondSpring's latest reported quarter, Q2 2026, generated $0 in revenue.
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BeyondSpring source filings ↗BeyondSpring ($BYSI) said the FDA granted Fast Track designation to plinabulin plus docetaxel for a defined previously treated non-squamous lung-cancer population. Separately, it signed an agreement to sell the holding company controlling i ...